Halo just signed a potentially billion dollar deal with BMY not to mention the deal.with ROCHE plus the drugs they have on their pipilne.
Harry Boxer has posted his Charts of the Day video on HALO at TheTechTrader site noting: Halozyme Therapeutics, Inc. (HALO) popped 47 cents, or 3%, to 16.72, on 5.8 million shares traded on Monday, and got all the way up to 17.55 before backing off. The target was 18.00. I think this stock may back and fill. It looks to me like it’s going to be a major short squeeze with 27 days to cover.
Hi guys, when did HALO dilute last? Is there any chance they might attempt it now given that they have increased revenue from these collaborations? thoughts please
CEO is negotiating New salary. Looking for 30 million a year plus additional stock options of about 10 million shares. Since she blows the Board, she'll get whatever she asks for. Can't see stock price moving higher than a few bucks.
Enhanze is a gold mine. BMS will pay 160 million for EACH drug that is delivered via Enhanze (and 105M up front) up to $2 billion! Roche deal seems even richer, with ongoing royalties on sales. I've been a patient long with paper losses for a long time on HALO. Not selling until it at least doubles from here. It ought to triple.
So, who was silly enough to listen to listen to believe Sandy or Paul, and sell into the brief, early morning dip? Because according to their logic, a biotech that has effectively doubled its revenue overnight, and gone into the black on earnings, is supposed to sell off... (and pigs fly).
Another deal on the books for HALO. 30mil cash, 160mil milestone payments, and a mid single digit %. Note previous deals were at low single digit %.
Ah, the poor shorts. Back to your dumpsters from whence you came.
Did anyone read what Paul the Short just posted? "Give it time! This partnership will dissolve when Roche realizes....." Seriously Paul...
Going back to the $12 range. Keep shorting this Pig!!!
"Company promises but never delivers. Total farce!!" I believe those were Paul Shorts words...Paul??
If the guidance Halo has provided, based on this capital injection is accurate, my guess analysts will be weighing in north of $30 in the next few days. "Net revenue should be $245M - 260M, up from $115M - 130M. Cash flow ops will be positive $50M - 60M, up from cash consumption of $75M - 85M." Really ~ they just doubled revenue and went positive on EPS.
Seriously - I can almost guarantee that the vast majority of these "shorts" have no positions. They typically would be typing this stuff from their mom's basement and getting paid by a hedge fund for each post & response. Ignore them. "Hey ma, can you get me a sandwich and can of RedBull - I have a lot of typing to do today."
With its deal with BMY and ROCHE, plus the P3 pancreatic cancer study which is consistently giving great results. Do you think HALO can be a great buyout target, or can it achieve the sustainability to perform as a future large cap biotech company?
Watch for misguided study and partners backing out! Coming soon!
Hello wallstreet anyone following this stock. I think some buy calls and increased price targets are warranted.
considering getting in, but what's the chance they issue more shares?
Perhaps, HALO could give a one time dividend $1.50 to $2.00 and a quarterly div of ,25. This would send share price thru the ceiling.